Choice of the denominator in case population studies: Event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 2, 2013, Pages 160-167

  Moore, Nicholas ^a,b,c   Gulmez, Sinem Ezgi ^a,b   Larrey, Dominique ^d   Pageaux, Georges Philippe ^d   Lignot, Séverine ^a,b   Lassalle, Régis ^a,b   Jové, Jérémy ^a,b   Pariente, Antoine ^a,b,c   Blin, Patrick ^a,b   Bénichou, Jacques ^c,e   Bégaud, Bernard ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c INSERM U657   (France)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

Case population study; Denominator; Drug induced liver injury; Event rate; Liver transplantation; NSAID; Paracetamol; Pharmacoepidemiology

Indexed keywords

DICLOFENAC; IBUPROFEN; KETOPROFEN; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ACUTE LIVER FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EXPOSURE; FRANCE; HUMAN; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOXIC HEPATITIS;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CHOICE BEHAVIOR; DRUG-INDUCED LIVER INJURY; FEMALE; FRANCE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; REGISTRIES; RETROSPECTIVE STUDIES; WAITING LISTS; YOUNG ADULT;

EID: 84873441890     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3371     Document Type: Article

References (20)

1. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15(4): 213-20. DOI: 10.1002/pds.1207
2. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf 2010; 19(7): 708-14. DOI: 10.1002/pds.1966
3. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327(7405): 18-22. DOI: 10.1136/bmj.327.7405.18327/7405/18 [pii]
4. Gulmez SE, Lignot-Maleyran S, Devries CS, et al. Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Saf 2012; 21(8): 851-856. DOI: 10.1002/pds.3204
5. Theophile H, Laporte JR, Moore N, Martin KL, Begaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf 2011; 34(10): 861-8. DOI: 10.2165/11592140-000000000-000006 [pii]
6. Capella D, Pedros C, Vidal X, Laporte JR. Case-population studies in pharmacoepidemiology. Drug Saf 2002; 25(1): 7-19.
7. Anonymous. Guidelines for ATC classification and DDD assignment. 4th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2001.
8. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 2010; 19(3): 256-65. DOI: 10.1002/pds.1912
9. Gulmez SE, Larrey D, Pageaux GP, et al. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol 2012. DOI: 10.1007/s00228-012-1357-8
10. Abenhaim L, Moore N, Begaud B. The role of pharmacoepidemiology in pharmacovigilance: A conference at the 6th ESOP meeting, Budapest, September 28, 1998. Pharmacoepidemiol Drug Saf 1999; 8: S1-S7.
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8, 2 p following 8. DOI: 10.1056/NEJM200011233432103
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11): 1092-102. DOI: NEJMoa050493 [pii]10.1056/NEJMoa050493
13. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47(7): 731-7.
14. Moore N, Van Ganse E, Le Parc J, et al. The PAIN study: Paracetamol, Aspirin and Ibuprofen New tolerability study. A large scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 89-98. DOI: 1173-2563/99/0008-0089
15. Hasford J, Moore N, Hoye K. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. Int J Clin Pharmacol Ther 2004; 42(8): 415-22.
16. Moore N, Diris H, Martin K, et al. NSAID use profiles derived from reimbursement data in France. Therapie 2004; 59(5): 541-6.
17. Moore N, Verschuren X, Montout C, Callens J, Kong SX, Begaud B. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55(1): 133-6.
18. Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007; 16(8): 891-900. DOI: 10.1002/pds.1388
19. Depont F, Fourrier A, Merliere Y, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf 2007; 16(5): 571-80. DOI: 10.1002/pds.1348
20. Moore N. Place of OTC analgesics and NSAIDs in osteoarthritis. Inflammopharmacology 2003; 11(4): 355-62.